2. Academic Validation
  3. Edoxaban: A Comprehensive Review of the Pharmacology and Clinical Data for the Management of Atrial Fibrillation and Venous Thromboembolism

Edoxaban: A Comprehensive Review of the Pharmacology and Clinical Data for the Management of Atrial Fibrillation and Venous Thromboembolism

  • Cardiol Ther. 2016 Jun;5(1):1-18. doi: 10.1007/s40119-016-0058-2.
Zachary A Stacy 1,  William B Call 2,  Aaron P Hartmann 2,  Golden L Peters 2,  Sara K Richter 3
Affiliations

Affiliations

  • 1 St. Louis College of Pharmacy, Cardiology, Mercy Hospital St. Louis, St. Louis, MO, USA. zstacy@stlcop.edu.
  • 2 St. Louis College of Pharmacy, Internal Medicine, Barnes-Jewish Hospital, St. Louis, MO, USA.
  • 3 St. Louis College of Pharmacy, Ambulatory Care, VA St. Louis Health Care System-John Cochran Division, St. Louis, MO, USA.
PMID: 26935434 DOI: 10.1007/s40119-016-0058-2
Abstract

Historically, vitamin K antagonists have been the only class of oral anticoagulants available. Despite our experience with warfarin over the past 60 years, its use is associated with several pharmacokinetic and clinical disadvantages including unpredictable dosing, frequent monitoring, and delayed onset and offset. Edoxaban, an oral direct Xa inhibitor, may provide clinicians with an additional option in patients requiring chronic anticoagulation. This review examines the pharmacology and clinical data of edoxaban as a therapeutic alternative.

Keywords

Atrial fibrillation; Direct oral anticoagulant (DOAC); Edoxaban; Factor Xa; Factor Xa inhibitor; Non-vitamin K oral anticoagulant (NOAC); Target-specific oral anticoagulant; Venous thromboembolism; Warfarin.

Figures
Products